Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)

NCT05629065 is registered in ClinicalTrials.gov with Dana-Farber Cancer Institute as lead sponsor.

NCT NCT05629065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05629065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pathways to Advance Targeted and Helpful Serious Illness Conversations (PATH-SIC)
Lead sponsor
Dana-Farber Cancer Institute
Phase
Not applicable
Overall status
Active, not recruiting
Start date
November 28, 2022
Completion date
June 30, 2028
Enrollment
800 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, gastrointestinal cancer, genitourinary cancer, gynecologic cancer, thoracic cancer